Chadi hosts two thoracic oncologists to dish and debate on the nuances of lung cancer screening: Charu Aggarwal, MD, MPH, University of Pennsylvania, and Lecia Sequist, MD, MPH, Massachusetts General Hospital and Harvard Medical School. The trio start by making the case for screening the healthy, low-risk population as well as people with a smoking history, and then jump into a round-up of clinical trials that have shown a positive impact from screening. The highly-questioned JAMA publication on the USPSTF recommendations for lung cancer screening is brought to the table, including the risks and scalability across larger and smaller hospital systems. No stone is left unturned in this riveting dialogue.
View the JAMA publication on screening for lung cancer jamanetwork.com/journals/jama/fullarticle/2777244
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
